Evaluation of Cannabidiol in Animal Seizure Models by the Epilepsy Therapy Screening Program (ETSP)

[1]  J. Rausch,et al.  The impact of nonadherence to antiseizure drugs on seizure outcomes in an animal model of epilepsy , 2017, Epilepsia.

[2]  M. Haney,et al.  Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers. , 2017, Drug and alcohol dependence.

[3]  T. Tomson,et al.  Progress report on new antiepileptic drugs: A summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII) , 2017, Epilepsia.

[4]  D. Reddy.  The Utility of Cannabidiol in the Treatment of Refractory Epilepsy , 2017, Clinical pharmacology and therapeutics.

[5]  E. Thiele,et al.  Cannabidiol as a new treatment for drug‐resistant epilepsy in tuberous sclerosis complex , 2016, Epilepsia.

[6]  T. Cummins,et al.  Aberrant epilepsy-associated mutant Nav1.6 sodium channel activity can be targeted with cannabidiol. , 2016, Brain : a journal of neurology.

[7]  A. Depaulis,et al.  Differential Effects of Antiepileptic Drugs on Focal Seizures in the Intrahippocampal Kainate Mouse Model of Mesial Temporal Lobe Epilepsy , 2016, CNS neuroscience & therapeutics.

[8]  K. Wilcox,et al.  Neuronal Injury, Gliosis, and Glial Proliferation in Two Models of Temporal Lobe Epilepsy , 2016, Journal of neuropathology and experimental neurology.

[9]  Anup D. Patel,et al.  Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial , 2016, The Lancet Neurology.

[10]  A. Coppola,et al.  From Cannabis to Cannabidiol to Treat Epilepsy, Where Are We? , 2016, Current pharmaceutical design.

[11]  F. Khodagholi,et al.  Cannabidiol Post-Treatment Alleviates Rat Epileptic-Related Behaviors and Activates Hippocampal Cell Autophagy Pathway Along with Antioxidant Defense in Chronic Phase of Pilocarpine-Induced Seizure , 2016, Journal of Molecular Neuroscience.

[12]  R. Laprairie,et al.  Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor , 2015, British journal of pharmacology.

[13]  Michael Bazelot,et al.  Molecular Targets of Cannabidiol in Neurological Disorders , 2015, Neurotherapeutics.

[14]  E. Thiele,et al.  Drug–drug interaction between clobazam and cannabidiol in children with refractory epilepsy , 2015, Epilepsia.

[15]  C. You,et al.  High dosage of cannabidiol (CBD) alleviates pentylenetetrazole-induced epilepsy in rats by exerting an anticonvulsive effect. , 2015, International journal of clinical and experimental medicine.

[16]  Shaun A. Hussain,et al.  Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox–Gastaut syndrome , 2015, Epilepsy & Behavior.

[17]  Y. Hurd,et al.  Safety and Pharmacokinetics of Oral Cannabidiol When Administered Concomitantly With Intravenous Fentanyl in Humans , 2015, Journal of addiction medicine.

[18]  J. Szaflarski,et al.  Cannabis, cannabidiol, and epilepsy — From receptors to clinical response , 2014, Epilepsy & Behavior.

[19]  Benjamin J. Whalley,et al.  Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability. , 2014, ACS chemical neuroscience.

[20]  R. Kaminski,et al.  Low potency and limited efficacy of antiepileptic drugs in the mouse 6Hz corneal kindling model , 2014, Epilepsy Research.

[21]  Benjamin J. Whalley,et al.  Voltage-gated sodium (NaV) channel blockade by plant cannabinoids does not confer anticonvulsant effects per se , 2014, Neuroscience Letters.

[22]  B. Vickrey,et al.  Cannabinoids for epilepsy. , 2014, The Cochrane database of systematic reviews.

[23]  F. Guimarães,et al.  Effects of intra-prelimbic prefrontal cortex injection of cannabidiol on anxiety-like behavior: Involvement of 5HT1A receptors and previous stressful experience , 2014, European Neuropsychopharmacology.

[24]  Dieter Schmidt,et al.  New avenues for anti-epileptic drug discovery and development , 2013, Nature Reviews Drug Discovery.

[25]  K. Wilcox,et al.  Rapid loss of efficacy to the antiseizure drugs lamotrigine and carbamazepine: A novel experimental model of pharmacoresistant epilepsy , 2013, Epilepsia.

[26]  H. White,et al.  Carbamazepine, but not valproate, displays pharmacoresistance in lamotrigine-resistant amygdala kindled rats , 2013, Epilepsy Research.

[27]  W. Theodore,et al.  Serotonin 1A receptors, depression, and memory in temporal lobe epilepsy , 2012, Epilepsia.

[28]  B. Platt,et al.  Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ9-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive–compulsive behaviour , 2012, Psychopharmacology.

[29]  K. Wilcox,et al.  Discovery of antiepileptic drugs , 2011, Neurotherapeutics.

[30]  S. Charpier,et al.  Involvement of the Thalamic Parafascicular Nucleus in Mesial Temporal Lobe Epilepsy , 2010, The Journal of Neuroscience.

[31]  H. White,et al.  Comparative anticonvulsant efficacy in the corneal kindled mouse model of partial epilepsy: Correlation with other seizure and epilepsy models , 2010, Epilepsy Research.

[32]  R. Fujinami,et al.  Development of Postinfection Epilepsy After Theiler's Virus Infection of C57BL/6 Mice , 2010, Journal of neuropathology and experimental neurology.

[33]  Stephen P. H. Alexander,et al.  International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB1 and CB2 , 2010, Pharmacological Reviews.

[34]  H. Kupferberg,et al.  The early identification of anticonvulsant activity: role of the maximal electroshock and subcutaneous pentylenetetrazol seizure models , 1995, The Italian Journal of Neurological Sciences.

[35]  Piotr Czapiński,et al.  Mechanisms of action of antiepileptic drugs. , 2005, Current topics in medicinal chemistry.

[36]  Wolfgang Löscher,et al.  The neurobiology of antiepileptic drugs , 2004, Nature Reviews Neuroscience.

[37]  A. Depaulis,et al.  Evolution of hippocampal epileptic activity during the development of hippocampal sclerosis in a mouse model of temporal lobe epilepsy , 2002, Neuroscience.

[38]  M. Barton,et al.  Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy , 2001, Epilepsy Research.

[39]  B. Martin,et al.  Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects. , 2001, European journal of pharmacology.

[40]  R. Post,et al.  Lamotrigine Treatment During Amygdala‐Kindled Seizure Development Fails to Inhibit Seizures and Diminishes Subsequent Anticonvulsant Efficacy , 2000, Epilepsia.

[41]  H. Klitgaard,et al.  Validation of corneally kindled mice: a sensitive screening model for partial epilepsy in man , 1998, Epilepsy Research.

[42]  R. Racine,et al.  Modification of seizure activity by electrical stimulation. II. Motor seizure. , 1972, Electroencephalography and clinical neurophysiology.

[43]  N W DUNHAM,et al.  A note on a simple apparatus for detecting neurological deficit in rats and mice. , 1957, Journal of the American Pharmaceutical Association. American Pharmaceutical Association.

[44]  L. Goodman,et al.  Comparative assay of an antiepileptic drugs by psychomotor seizure test and minimal electroshock threshold test. , 1953, The Journal of pharmacology and experimental therapeutics.

[45]  F. M. Wadley.  Probit Analysis: A Statistical Treatment of the Sigmoid Response Curve . 2nd ed. D. J. Finney. New York-London: Cambridge Univ. Press, 1952. 318 pp. $7.00 , 1952, Science.

[46]  D. J. Finney.  Probit analysis; a statistical treatment of the sigmoid response curve. , 1947 .